These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
234 related items for PubMed ID: 17570469
1. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Kivitz AJ, Espinoza LR, Sherrer YR, Liu-Dumaw M, West CR. Semin Arthritis Rheum; 2007 Dec; 37(3):164-73. PubMed ID: 17570469 [Abstract] [Full Text] [Related]
2. A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms. Williams GW, Kivitz AJ, Brown MT, Verburg KM. Clin Ther; 2006 Feb; 28(2):204-21. PubMed ID: 16678642 [Abstract] [Full Text] [Related]
3. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study. Gibofsky A, Rodrigues J, Fiechtner J, Berger M, Pan S. Clin Ther; 2007 Jun; 29(6):1071-85. PubMed ID: 17692722 [Abstract] [Full Text] [Related]
4. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. Birbara C, Ruoff G, Sheldon E, Valenzuela C, Rodgers A, Petruschke RA, Chang DJ, Tershakovec AM. Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445 [Abstract] [Full Text] [Related]
5. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. Barkhuizen A, Steinfeld S, Robbins J, West C, Coombs J, Zwillich S. J Rheumatol; 2006 Sep; 33(9):1805-12. PubMed ID: 16960941 [Abstract] [Full Text] [Related]
6. A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. Foeldvari I, Szer IS, Zemel LS, Lovell DJ, Giannini EH, Robbins JL, West CR, Steidle G, Krishnaswami S, Bloom BJ. J Rheumatol; 2009 Jan; 36(1):174-82. PubMed ID: 19012356 [Abstract] [Full Text] [Related]
7. Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. Smugar SS, Schnitzer TJ, Weaver AL, Rubin BR, Polis AB, Tershakovec AM. Curr Med Res Opin; 2006 Jul; 22(7):1353-67. PubMed ID: 16834834 [Abstract] [Full Text] [Related]
8. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults. Kivitz A, Fairfax M, Sheldon EA, Xiang Q, Jones BA, Gammaitoni AR, Gould EM. Clin Ther; 2008 Dec; 30(12):2366-77. PubMed ID: 19167595 [Abstract] [Full Text] [Related]
9. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial. Ogrendik M. Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134 [Abstract] [Full Text] [Related]
10. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, Regourd E, May M. Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556 [Abstract] [Full Text] [Related]
11. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Dougados M, Béhier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, Zeidler H, Herman H. Arthritis Rheum; 2001 Jan; 44(1):180-5. PubMed ID: 11212158 [Abstract] [Full Text] [Related]
12. Analgesic efficacy of celecoxib in postoperative oral surgery pain: a single-dose, two-center, randomized, double-blind, active- and placebo-controlled study. Cheung R, Krishnaswami S, Kowalski K. Clin Ther; 2007 Jan; 29 Suppl():2498-510. PubMed ID: 18164917 [Abstract] [Full Text] [Related]
13. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Gibofsky A, Williams GW, McKenna F, Fort JG. Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272 [Abstract] [Full Text] [Related]
14. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699 [Abstract] [Full Text] [Related]
15. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen. Ta LE, Dionne RA. Pain; 2004 Sep; 111(1-2):13-21. PubMed ID: 15327804 [Abstract] [Full Text] [Related]
16. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial. Lü LJ, Teng JL, Bao CD, Han XH, Sun LY, Xu JH, Li XF, Wu HX. Chin Med J (Engl); 2008 Apr 05; 121(7):615-9. PubMed ID: 18466681 [Abstract] [Full Text] [Related]
17. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies. Daniels S, Robbins J, West CR, Nemeth MA. Clin Ther; 2009 Jun 05; 31(6):1192-208. PubMed ID: 19695387 [Abstract] [Full Text] [Related]
18. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk FG, Mease P, Treatment of Psoriatic Arthritis Study Group. Arthritis Rheum; 2004 Jun 05; 50(6):1939-50. PubMed ID: 15188371 [Abstract] [Full Text] [Related]
19. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS. Arthritis Rheum; 2002 Dec 05; 46(12):3143-50. PubMed ID: 12483717 [Abstract] [Full Text] [Related]
20. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS. Clin Ther; 2005 Jan 05; 27(1):64-77. PubMed ID: 15763607 [Abstract] [Full Text] [Related] Page: [Next] [New Search]